Dyslipidemia GUIDELINES Pocket Guide

Approved By

National Lipid Association

Digital Subscription $4.99 Add to Cart
Print $10.95 Add to Cart
Free Sample

The digital subscription version of the Dyslipidemia GUIDELINES Pocket Guide contains all the same great information found in the physical pocket guide, and can be accessed on mobile devices and online:

  • Price: $4.99 per year
    • Subscribe to additional guideline titles for discounted rates
  • Includes automatic updates during the term of your subscription
  • CPT® and ICD10 codes can be added to certain guidelines for an additional fee
  • Supported platforms
    • iPhone and iPad
    • Android phones and tablets
    • Online (internet connection required)
  • Content on the Guideline Central mobile app accessible without an internet connection
    • Access to additional guideline summaries, clinical calculators, and more

For mobile access, download the free app from the App Store or Google Play and use the same email address and password as the website to login.

For individual use only; contact us for group and site licenses.

The Dyslipidemia  GUIDELINES Pocket Guide is based on the latest guidelines of the National Lipid Association and was developed with their collaboration. This practical quick-reference tool contains comprehensive risk assessment recommendations, multiple factors that affect lipid levels, treatment recommendations for both lifestyle and drug and apheresis therapy, and detailed information on pharmaceutical agents.


  • Spiral Bound
  • 18 pages
  • 80# Diamond Silk Cover with Satin Aqueous Coating
  • 4.5″ x 7.25″
  • Key Points
  • Risk Assessment
  • Treatment Recommendations
  • Algorithms
    • Model of Steps in Lifestyle Therapies
    • Progression of Atherogenic-Cholesterol-Lowering Drug Therapy
  • Tables
    • Criteria for Classification of ASCVD
    • Major Risk Factors for ASCVD
    • Risk Calculators
    • Criteria for ASCVD Risk Assessment, Treatment Goals for Atherogenic Cholesterol, and Levels at Which to Consider Drug Therapy
    • High or Very High-Risk Patient Groups
    • Sequential Steps in ASCVD Risk Assessment
    • Classifications of Cholesterol and Triglyceride Levels
    • Drugs That May Elevate LDL-C or Triglyceride Concentrations
    • Risk Indicators (Other Than Major ASCVD Risk Factors) That Might be Considered for Risk Refinement
    • Diet Characteristics and Diseases/Disorders/Altered Metabolic States That May Elevate LDL-C and/or Triglyceride Concentrations
    • Criteria for Clinical Identification of the Metabolic Syndrome
    • Treatment Goals for Non-HDL-C, LDL-C, and Apo B
    • The intensity of Statin Therapy
    • Apheresis
    • Available drugs and Their Effects on Lipid Metabolism
    • Agents for Homozygous Familial Hypercholesterolemia

The National Lipid Association (NLA) is a nonprofit, multidisciplinary medical society focused on enhancing the practice of lipid management in clinical medicine. The NLA represents more than 3,500 members in the United States and provides continuing medical education for physicians and other healthcare professionals to advance professional development and attain certification in clinical lipidology. The NLA's public health mission is to help reduce deaths related to high cholesterol, and the Association defines "clinical lipidology" as "a multidisciplinary branch of medicine focusing on lipid and lipoprotein metabolism and their associated disorders."

  • Guideline Pricing

  • Single Title
    $4.99 / year
  • Any 5 Titles
    $23.99 / year
  • Any 10 Titles
    $41.99 / year
  • Any 35 Titles
    $74.99 / year
  • All Available Titles
    $169.99 / year

To get started, log in or create your free account Create Account